Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma.

Authors:
Susumu Maruta Sadahisa Ogasawara Yoshihiko Ooka Masamichi Obu Masanori Inoue Norio Itokawa Yuki Haga Atsuyoshi Seki Shinichiro Okabe Ryosaku Azemoto Ei Itobayashi Masanori Atsukawa Nobuyuki Sugiura Hideaki Mizumoto Keisuke Koroki Kengo Kanayama Hiroaki Kanzaki Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Tomoko Saito Takayuki Kondo Eiichiro Suzuki Shingo Nakamoto Akinobu Tawada Tetsuhiro Chiba Makoto Arai Tatsuo Kanda Hitoshi Maruyama

Liver Cancer 2020 Aug 5;9(4):382-396. Epub 2020 May 5.

Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Background: The present study aimed to assess the efficacy and safety of lenvatinib and verify the possibility of lenvatinib for the expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma (HCC) in real-world practice, primarily focusing on the population that was excluded in the REFLECT trial.

Methods: We retrospectively collected data on patients with advanced HCC who were administered lenvatinib in 7 institutions in Japan.

Results: Of 152 advanced HCC patients, 95 and 57 patients received lenvatinib in first-line and second- or later-line systemic therapies, respectively. The median progression-free survival in Child-Pugh class A patients was nearly equal between first- and second- or later-line therapies (5.2 months; 95% CI 3.7-6.9 for first line, 4.8 months; 95% CI 3.8-5.9 for second or later line, = 0.933). According to the modified Response Evaluation Criteria in Solid Tumors, the objective response rate of 27 patients (18%) who showed a high burden of intrahepatic lesions (i.e., main portal vein and/or bile duct invasion or 50% or higher liver occupation) at baseline radiological assessment was 41% and similar with that of other population. The present study included 20 patients (13%) with Child-Pugh class B. These patients observed high frequency rates of liver function-related adverse events due to lenvatinib. The 8-week dose intensity of lenvatinib had a strong correlation with liver function according to both the Child-Pugh and albumin - bilirubin scores.

Conclusion: Lenvatinib had potential benefits for patients with advanced HCC with second- or later-line therapies and a high burden of intrahepatic lesions. Dose modification should be paid increased attention among patients with poor liver function, such as Child-Pugh class B patients.

Download full-text PDF

 Source
http://dx.doi.org/10.1159/000507022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506220PMC
August 2020

Publication Analysis

Top Keywords

patients advanced
16
second- later-line
12
class patients
12
child-pugh class
12
advanced hcc
12
patients
12
high burden
8
burden intrahepatic
8
intrahepatic lesions
8
liver function
8
function child-pugh
8
advanced hepatocellular
8
months 95%
8
hepatocellular carcinoma
8
reflect trial
8
lenvatinib expanded
8
expanded indication
8
later-line therapies
8
indication reflect
8
trial patients
8

Keyword Occurance

Similar Publications

The comprehensive expression and functional analysis of m6A modification "readers" in hepatocellular carcinoma.

Authors:
Sha Qin Gaoming Liu Haoer Jin Xue Chen Jiang He Juxiong Xiao Yan Qin Yitao Mao Luqing Zhao

Aging (Albany NY) 2022 Aug 12;14(undefined). Epub 2022 Aug 12.

Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

N6-methyladenosine (m6A) modification regulators are essential for the diagnosis and treatment of various cancers. However, the comprehensive analysis about roles of m6A "readers" in hepatocellular carcinoma (HCC) remains unclear. UALCAN, GEPIA2, HPA, Kaplan Meier plotter, cBioPortal, STRING WebGestalt, Metascape and TIMER 2. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Artificial Intelligence-based Prediction of Clinical Outcome in Immunotherapy and Targeted Therapy of Lung Cancer.

Authors:
Xiaomeng Yin Hu Liao Hong Yun Nan Lin Shen Li Yu Xiang Xuelei Ma

Semin Cancer Biol 2022 Aug 10. Epub 2022 Aug 10.

Department of Biotherapy, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, No. 37 GuoXue Alley, Chengdu 610041, China. Electronic address:

Lung cancer accounts for the main proportion of malignancy-related deaths and most patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have great advances in application in clinics to treat lung cancer patients, yet the efficacy is unstable. The response rate of these therapies varies among patients. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Novel Therapy for Recanalization of Chronic Iliocaval Venous Occlusion Using Radiofrequency.

Authors:
Jacob Shapiro Evan Neville Brent Robertson L Graham Rucker Angela N Fellner Brian Kuhn Matthew Recht Aaron Kulwicki Mark Broering Patrick Muck

J Vasc Surg Venous Lymphat Disord 2022 Aug 10. Epub 2022 Aug 10.

Department of Vascular Surgery, Good Samaritan & Bethesda North Hospital, Cincinnati, OH.

Objective: Chronic venous disease of the lower extremities is one of the most common diseases in the U.S. The sequelae of this disease process are the source of a significant amount of morbidity, and its prevalence is expected to increase in the coming decades. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thicknesses in Hydroxychloroquine Retinopathy.

Authors:
Ko Eun Kim Young Hwan Kim Jiyeong Kim Seong Joon Ahn

Am J Ophthalmol 2022 Aug 10. Epub 2022 Aug 10.

Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea. Electronic address:

Objective: To investigate macular ganglion cell complex (GCC) and peripapillary retinal nerve fiber layer (RNFL) thicknesses in patients with hydroxychloroquine retinopathy of differing severity.

Design: Cross-sectional, case-control comparison study.

Participants: From patients screened for hydroxychloroquine retinopathy between January 2016 and October 2021 using swept-source optical coherence tomography (SS-OCT), fundus autofluorescence (FAF), and standard automated perimetry, 66 patients with retinopathy and 66 without retinopathy were included by 1:1 propensity score matching based on age, sex, systemic diseases, history of tamoxifen and pentosan use, and kidney disease. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Folliculotropic Mycosis Fungoides in a Latin American Hospital: Survival Analysis.

Authors:
H C Pérez S D Morales L Enciso A Carreño X Rueda

Actas Dermosifiliogr 2022 Aug 10. Epub 2022 Aug 10.

Dermatología Oncológica, Instituto Nacional de Cancerología, Universidad Militar Nueva Granada, Bogotá, Colombia.

Background: Folliculotropic mycosis fungoides (FMF) has a poor prognosis and a variable clinical presentation. Concerns have been expressed that the current TNMB staging of this tumor may not be useful. A recently developed classification system based on clinical and histologic variables classifies this tumor as early or advanced, a distinction found to correlate with prognosis. Read More

View Article and Full-Text PDF
August 2022
Similar Publications
}